Citigroup Initiates Coverage On Acumen Pharmaceuticals with Buy Rating, Announces Price Target of $7
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst David Hoang has initiated coverage on Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy rating and set a price target of $7.

July 25, 2024 | 9:19 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Citigroup analyst David Hoang has initiated coverage on Acumen Pharmaceuticals with a Buy rating and set a price target of $7.
The initiation of coverage with a Buy rating and a specific price target by a major financial institution like Citigroup is likely to positively impact the stock price of Acumen Pharmaceuticals in the short term. This is because such coverage often increases investor confidence and can attract new investments.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100